Cell metabolism, 2021-04, Vol.33 (4), p.705-706
2021
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Obesity therapeutics: The end of the beginning
- Ist Teil von
- Cell metabolism, 2021-04, Vol.33 (4), p.705-706
- Ort / Verlag
- United States
- Erscheinungsjahr
- 2021
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Obese non-diabetic patients receiving semaglutide, an injectable long-acting GLP-1 receptor agonist, in a large randomized placebo-controlled trial, lost and maintained ∼15% of their body weight for over a year (Wilding et al., 2021). This impressive result is likely to usher in a new era of anti-obesity drugs based on hormones that suppress food intake, largely through acting on the brain.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1550-4131eISSN: 1932-7420DOI: 10.1016/j.cmet.2021.03.012Titel-ID: cdi_proquest_miscellaneous_2510290295
- Format
- –
- Schlagworte
- Anti-Obesity Agents - therapeutic use, Body Weight, Double-Blind Method, Humans, Obesity - drug therapy